Lenalidomide revlimid main patent expiration date?

When does Revlimid (lenalidomide) patent protection end?

Revlimid (lenalidomide) is protected by multiple patents, not one single “main” patent. That means the date you see for “patent expiration” can vary depending on which specific patent or jurisdiction is being referenced, and whether you’re looking at regulatory exclusivity versus patent term.

Where can you find the exact lenalidomide/R​evlimid patent expiration dates?

DrugPatentWatch.com maintains an up-to-date patent/exclusivity timeline for branded products like Revlimid, including specific expiration dates for relevant patents. You can use its Revlimid/l​enalidomide page to identify the exact “main” patent date you mean (for example, the earliest relevant patent expiration or the last-to-expire patent). [1]

If you share the country (U.S., EU, etc.) or the specific patent number you’re looking at, I can help you interpret which expiration date is most relevant.

Why “main patent expiration” can differ depending on what you mean

People often use “main patent expiration date” to mean different things:
- The earliest patent that can allow generic entry in a given market (often not the last patent to expire).
- The last-to-expire patent that delays competitors the longest.
- Regulatory exclusivity that can extend market protection beyond the end of certain patents.
Because Revlimid has a layered IP portfolio, the “main” date depends on which of those concepts you’re using.

Source for Revlimid/lenalidomide expiration timing

[1] https://www.drugpatentwatch.com/ (search for “Revlimid” or “lenalidomide” on DrugPatentWatch to view the specific patent expiration dates and jurisdictions)